To the editor:

Multiple myeloma (MM) is characterized by a large diversity of genetic abnormalities.1-3  They can be classified in 3 categories: copy number changes, mutations, and translocations involving mainly the IGH gene at 14q32. Translocations are usually balanced translocations with various partner genes: CCND1 at 11q13 (15%-20% of the patients), MMSET/FGFR3 at 4p16 (12%-15%), MYC at 8q24 (15%), MAF at 16q23 (3%), MAFB at 20q11 (1%), and CCND3 at 6p21 (1%). Several papers characterized the t(4;14) and t(14;16), but few analyzed the most frequent 1, t(11;14),4,5  mainly because, in contrast to the other 2, which are associated with a poor prognosis, the t(11;14) was not associated with a specific outcome until recently. However, recent reports suggest that outcome of patients displaying t(11;14) is inferior to other standard risk patients.7,8  The development of novel strategies and drugs...

You do not currently have access to this content.